Skip to main content
NCBI home page
RSC Advances logoLink to RSC Advances
. 2020 Jan 9;10(4):2016–2026. doi: 10.1039/c9ra10194b

Visible-light-induced aerobic C3–H fluoroalkoxylation of quinoxalin-2(1H)-ones with fluoroalkyl alcohols†

Xiaobo Xu 1,2, Chengcai Xia 1,✉, Xiaojun Li 3, Jian Sun 1, Liqiang Hao 1
PMCID: PMC9047172  PMID: 35494590

Abstract

A novel and efficient method of visible-light-induced C3–H fluoroalkoxylation of quinoxalin-2(1H)-ones with fluoroalkyl alcohols is developed. This approach uses readily available fluoroalkyl alcohols as fluoroalkoxylation reagents and displays a wide substrate scope, providing the fluoroalkoxylated products in moderate to good yields. Compared with the previous method, such a transformation uses oxygen as an oxidant, which avoids the utilization of plenty of PhI(TFA)2. In addition, this strategy also gives a practical tool for the rapid synthesis of histamine-4 receptor antagonist and new N-containing bidentate ligands. A radical mechanism was suggested according to the results of control experiments.

A visible-light-induced aerobic C3–H fluoroalkoxylation of quinoxalin-2(1H)-ones with fluoroalkyl alcohols was reported, providing a green access to fluoroalkoxylated quinoxalin-2(1H)-ones.graphic file with name c9ra10194b-ga.jpg

Introduction

As a class of fluorine-containing molecules, fluoroalkoxyl aryl ethers are widely used in agricultural agents, advanced materials and pharmaceuticals because of the unique impact of the fluorine atoms on physicochemical and biological properties.1 The conventional methods to prepare such compounds are nucleophilic aromatic substitution reactions (SNAr), which usually suffer from high temperature and low reactivity.2 Consequently, the development of more practical and efficient approaches to access fluoroalkoxyl aryl ethers has recently received considerable attention.

In recent years, transition-metal-catalyzed reactions have been regarded as reliable strategies for the preparation of fluoroalkoxyl aryl ethers.3 For example, Weng,3a,b Ji,3c Crousse,3d and Qing3e reported novel methods for the construction of fluoroalkoxyl aryl ethers through copper-catalyzed C–O cross couplings of aryl halides or aryl boronic acids with fluoroalkyl alcohols. In addition, the Singh group achieved a palladium-catalyzed dehalogenated coupling of aryl halides with fluoroalkyl alcohols for the synthesis of fluoroalkoxyl aryl ethers.3f Alternatively, palladium-catalyzed amide-directed C–H trifluoroethoxylation provided another route to fluoroalkoxyl aryl ethers.3g Despite the utilities, the pre-functionalization of the starting materials in above methods limited their applications. In addition, the metal catalysts are toxic, and trace amounts of metal residues in final products are quite difficult to remove, which is a crucial issue in the pharmaceutical industry.4

As an important class of heterocyclic units, quinoxalin-2(1H)-ones widely exist in natural products, organic intermediates and pharmaceuticals.5 Therefore, great efforts have been devoted to the development of new methods for the synthesis of quinoxalin-2(1H)-ones and its derivatives.6 Thanks to the development of C–H functionalization, lots of transformations so far have been achieved,7 such as phosphorization,8 amination,9 alkylation,10 arylation,11 acylation,12 trifluoromethylation,13 difluoromethylation,14 alkoxylation15 and thiolation.16 In sharp contrast, C–H fluoroalkoxylation of quinoxalin-2(1H)-ones was rarely reported. Very recently, the first example of C3–H fluoroalkoxylation of quinoxalin-2(1H)-ones with fluoroalkyl alcohols was reported by Li and Zhang (Scheme 1a).17 However, such reaction suffers from plenty of PhI(TFA)2, which failed to meet the requirements of green chemistry.18

Scheme 1. The C3–H fluoroalkoxylation of quinoxalin-2(1H)-ones.

Scheme 1

Open in a new tab

As a clean and sustainable approach, photocatalyzed C–H functionalization has become an important strategy to introduce fluorine-containing functional groups into organic molecules.19 For a long time, we are always working to develop photocatalyzed C–H functionalization of N-heterocycle.20 Recently, our group reported photocatalyzed aerobic C3–H perfluoroalkylation of quinoxalin-2(1H)-ones with sodium perfluoroalkanesulfinates.13a As a further work, herein, we demonstrated a visible light induced aerobic C3–H fluoroalkoxylation of quinoxalin-2(1H)-ones with fluoroalkyl alcohols, providing a green and efficient method to introduce fluoroalkoxy into quinoxalin-2(1H)-ones molecules (Scheme 1b). During the preparation of our manuscript, Wang and Li groups developed an useful approach for alkoxylation of quinoxalin-2(1H)-ones respectively, but it only gave one trifluoroethoxylated example.15a,b Therefore, the development of simple and widely applicable approaches for the C3–H fluoroalkoxylation of quinoxalin-2(1H)-ones is still meaningful. In addition, many further transformations have been done in our work, which clearly demonstrated the application value of the reaction.

Results and discussion

Initially, the coupling reaction of quinoxalin-2(1H)-ones with trifluoroethanol was performed in air by using 5 mol% of rose bengal as a photocatalyst under the radiation of 18 W blue LED. The desired product (2) was obtained in 25% yield (Table 1, entry 1). Encouraged by this result, we next screened a series of photocatalysts such as Acr+–Mes ClO4−, fluorescein, eosin Y, methylene blue, erythrosine, Ru(bpy)3Cl2 and Ir(ppy)3. It was found that eosin Y was the best photocatalyst, which provided the product in 70% yield (Table 1, entries 2–8). No desired product (2) was generated without photocatalyst (Table 1, entry 9). To further improve the product yield, some additives and solvents were explored, but no better result was gained (Table 1, entries 10–18). To our delight, the yield was enhanced to 85% when the reaction was performed under O2 atmosphere (Table 1, entry 19). No desired product was generated when the transformation was carried out under N2 atmosphere (Table 1, entry 20). These results implied that O2 played a key role in this transformation. Further investigations on the light sources revealed that blue light was the best choice for the reaction (Table 1, entries 21–23).

Optimization of reaction conditionsa,b.

graphic file with name c9ra10194b-u1.jpg
Entry Photocatalyst Additive Solvent Yieldb [%]
1 Rose bengal — — 25
2 Acr+–Mes ClO4− — — 65
3 Fluorescein — — Trace
4 Eosin Y — — 70
5 Methylene blue — — Trace
6 Erythrosine — — Trace
7 Ru(bpy)3Cl2 — — 28
8 Ir(ppy)3 — — Trace
9 — — — 0
10 Eosin Y TFA — 66
11 Eosin Y H3PO4 — 43
12 Eosin Y Na2CO3 — 20
13 Eosin Y AcONa — 34
14 Eosin Y Bu4NBr — 48
15c Eosin Y — CH3CN 52
16c Eosin Y — DCE Trace
17c Eosin Y — DMF 24
18c Eosin Y — H2O Trace
19d Eosin Y — — 85
20e Eosin Y — — 0
21d,f Eosin Y — — 15
22d,g Eosin Y — — 27
23d,h Eosin Y — — 0
Open in a new tab
a

Reaction conditions: 1a (0.2 mmol), photocatalyst (5 mol%), additive (1.5 equiv.), CF3CH2OH (0.5 mL), blue LED (18 W), rt, under air atmosphere, 24 h.

b

Isolated yields.

c

CF3CH2OH (5.0 equiv.), solvent (0.5 mL).

d

Under O2 atmosphere.

e

Under N2 atmosphere.

f

Green LED (18 W).

g

White LED (18 W).

h

Without light.

Having established the best reaction conditions, we subsequently explored the substrate scope of quinoxalin-2(1H)-ones (Table 2). Generally, the C–H fluoroalkoxylation reaction showed good substituent group tolerance. Quinoxalin-2(1H)-ones bearing different of N-protecting groups such as methyl (–CH3), ethyl (–C2H5), butyl (–nC4H9), isoamyl (–iC5H11), cyclopropylmethyl, cyclohexylmethyl and esteryl (–CH2CO2R) were well tolerant, giving the corresponding products (2–9) in 70–87% yields. The N-benzyl groups (–CH2Ar) also were compatible, affording the target products in good yields (10–19). The molecular structure of product 18 was confirmed by X-ray diffraction studies (see ESI†). In addition, quinoxalin-2(1H)-ones with substituents on the benzene ring also could undergo this transformation smoothly, providing the trifluoroethoxylated products (20–27) in 45–82% yields. Furthermore, quinoxalin-2(1H)-one and 2H-benzo[b][1,4]oxazin-2-one were also tolerant under standard reaction conditions, yielding the corresponding products (28 and 29) in 75% and 78% yields, responsively.

Substrate scope of quinoxalin-2(1H)-onesa,b.

graphic file with name c9ra10194b-u2.jpg
Open in a new tab
a

Reaction conditions: 1 (0.2 mmol), eosin Y (5 mol%), CF3CH2OH (0.5 mL), blue LED (18 W), rt, O2, 24 h.

b

Isolated yields.

After that, the efforts were further focused on the exploration of fluoroalkyl alcohols (Table 3). It was found that fluoroalkyl alcohols such as pentafluoro-1-propanol, heptafluoro-1-butanol, tetrafluoro-1-propanol, trifluorobutan-1-butanol, difluoro-1-ethanol and fluoro-1-ethanol could also undergo this reaction successfully, producing the corresponding products (30–41) in good yields. Regrettably, the longer-chain and bulky fluoroalkyl alcohols such as octafluoropentyl alcohol, hexafluoroisopropanol and nonafluoro-tert-butanol could not be converted into corresponding products (42–44) since the effect of large steric hindrance. We also tried to extend the method to the modification of other important N-containing molecules, but failed (see ESI, Scheme S1†).

Substrate scope of fluoroalkyl alcoholsa,b.

graphic file with name c9ra10194b-u3.jpg
Open in a new tab
a

Reaction conditions: 1 (0.2 mmol), eosin Y (5 mol%), RfOH (0.5 mL), blue LED (18 W), rt, O2, 24 h.

b

Isolated yields.

To demonstrate the application value of the reaction, we firstly performed a gram-scale reaction. To our delight, the product (2) could be isolated in 72% yield (Scheme 2a). In addition, the histamine-4 receptor antagonist 45 could be obtained in 63% yield through the C–H trifluoroethoxylation, followed by nucleophilic substitution (Scheme 2b).21 Furthermore, the N-containing bidentate ligand 46 also could be synthesized in 50% yield by using product 28 as building block (Scheme 3). We further applied this ligand to catalyse traditional C–N cross-couplings to examine its reactivity. It was found that compare to other ligands that were reported in the literature,22 the ligand 46 has relatively good reactivity, providing the product in moderate yield.

Scheme 2. Gram-scale synthesis and the synthesis of histamine-4 receptor antagonist.

Scheme 2

Open in a new tab

Scheme 3. Further chemistry.

Scheme 3

Open in a new tab

To obtain more details of the C–H fluoroalkoxylation reaction, the mechanism investigations were started. Firstly, the C–H fluoroalkoxylation reaction was dramatically suppressed when two equivalents of TEMPO (2,2,6,6-tetramethylpiperidinooxy) or DPE (1,1-diphenylethlene) was added respectively (Scheme 4). These results implied that a radical pathway might be involved in this reaction. The visible light irradiation on/off experiments revealed that the visible light played a crucial role in this reaction (Fig. 1). In addition, the measurement result of potential indicated that the generation of trifluoroethoxy radical from trifluoroethanol is very difficult (Scheme S2†).

Scheme 4. Mechanism studies.

Scheme 4

Open in a new tab

Fig. 1. Visible light irradiation on/off experiments.

Fig. 1

Open in a new tab

Based on the results of mechanism studies and previous works,7–17 we proposed a reasonable mechanism for this visible-light-induced C–H fluoroalkoxylation reaction (Scheme 5). Initially, the excited eosin Y* was generated under the irradiation of blue LEDs. A subsequent single-electron-transfer (SET) process took place between eosin Y* and N-methyl-quinoxalin-2(1H)-one 1a to form the eosin Y˙− species and intermediate A. The intermediate A was further trapped by trifluoroethanol to generate intermediate B. Meanwhile, the second single-electron-transfer (SET) process happened between eosin Y˙− species and O2 to give O2˙− species and eosin Y. The final product was obtained through oxidation and proton transfer process with the release of H2O2, which was detected by a starch potassium iodide test paper.

Scheme 5. Plausible mechanism.

Scheme 5

Open in a new tab

Conclusions

We have reported a visible-light-induced aerobic C3–H fluoroalkoxylation of quinoxalin-2(1H)-ones with fluoroalkyl alcohols. This approach uses readily available fluoroalkyl alcohols as fluoroalkoxylation reagents and substrates with various functional groups were tolerant, providing the fluoroalkoxylated products in moderate to good yields. The control experiments results demonstrated that a radical pathway was answerable for this reaction.

Experimental section

General information

The starting materials, solvents and other chemicals used in experiments were purchased from Energy Chemical without further purification. All products were isolated by short chromatography on a silica gel (200–300 mesh) column using petroleum ether (60–90 °C) and ethyl acetate. 1H, 13C and 19F NMR spectra were recorded on Bruker Avance DRX-500 spectrometers at ambient temperature with CDCl3 as solvent and tetramethylsilane (TMS) as the internal standard. All chemical shift values are quoted in ppm and coupling constants quoted in Hz. Compounds for HRMS were analyzed by positive mode electrospray ionization (ESI) using Agilent 6530 QTOF mass spectrometer.

General procedure for the synthesis of fluoroalkoxylated quinoxalin-2(1H)-ones (2–41)

Quinoxalin-2(1H)-ones derivatives 1 (0.2 mmol), eosin Y (5 mol%), RfOH (0.5 mL) were combined in a 15 mL tube. The mixture was then stirred for 24 hours under O2 atmosphere by the radiation of 18 W blue LED. After the conversion was completed as indicated by TLC, to the residue was added water (10 mL) and extracted with ethyl acetate (5 mL × 3). The collected organic layer was washed with brine, dried with MgSO4, filtered and concentrated in vacuo. The residue was purified directly by flash column chromatography.

General procedure for the gram-scale synthesis of fluoroalkoxylated quinoxalin-2(1H)-one (2)

Quinoxalin-2(1H)-ones derivatives 1a (10.0 mmol), eosin Y (5 mol%), RfOH (20 mL) were combined in a 100 mL flask. The mixture was then stirred for 24 hours under O2 atmosphere by the radiation of 18 W blue LED. After the conversion was completed as indicated by TLC, to the residue was added water (10 mL) and extracted with ethyl acetate (50 mL × 3). The collected organic layer was washed with brine, dried with MgSO4, filtered and concentrated in vacuo. The residue was purified directly by flash column chromatography.

General procedure for the synthesis of histamine-4 receptor antagonist (45)

Quinoxalin-2(1H)-ones derivative 1y (0.5 mmol), eosin Y (5 mol%), RfOH (1.0 mL) were combined in a 15 mL tube. The mixture was then stirred for 24 hours under O2 atmosphere by the radiation of 18 W blue LED. After the conversion was completed as indicated by TLC, to the residue was added water (10 mL) and extracted with ethyl acetate (10 mL × 3). The collected organic layer was washed with brine, dried with MgSO4, filtered and concentrated in vacuo. After the solvent was removed, DMSO (1.5 mL), Et3N (1.5 equiv.) and N-methylpiperazine (1.5 equiv.) were added to the residue, and the mixture was stirred at 120 °C for 12 hours. After the conversion was completed as indicated by TLC, to the residue was added water (10 mL) and extracted with ethyl acetate (10 mL × 3). The collected organic layer was washed with brine, dried with MgSO4, filtered and concentrated in vacuo. The residue was purified directly by flash column chromatography.

General procedure for the synthesis of 3,3′-bis(2,2,2-trifluoroethoxy)-2,2′-biquinoxaline (46)

Fluoroalkoxylated quinoxalin-2(1H)-one 28 (2.0 mmol), POCl3 (1.2 equiv.) and pyridine (1.0 equiv.) were combined in a 15 mL tube. The mixture was then stirred at 160 °C for 30 min. After the conversion was completed as indicated by TLC, to the residue was added saturated NaHCO3 solution (15 mL) and extracted with ethyl acetate (20 mL × 3). The collected organic layer was washed with brine, dried with MgSO4, filtered and concentrated in vacuo. After the solvent was removed, NiCl2·6H2O (5 mol%), LiCl (1.0 equiv.), zinc dust (1.2 equiv.) and DMF (10.0 mL) in a 50 mL flask was heated to 50 °C, then, a grain of iodine crystal and two drops of acetic acid were added to the mixture. The mixture was stirred at 60 °C for 2 hours. After the conversion was completed as indicated by TLC, to the residue was added water (15 mL) and extracted with ethyl acetate (20 mL × 3). The collected organic layer was washed with brine, dried with MgSO4, filtered and concentrated in vacuo. The residue was purified directly by flash column chromatography.

General procedure for the synthesis of 1-(p-tolyl)-1H-indole (49)

K3PO4 (2.2 mmol) was added to a Schlenk tube equipped with a stirring bar and the tube was dried under vacuum and then filled with an argon. CuI (0.1 mmol) and ligand (0.1 mmol) and DMF (4.0 mL) were added and the mixture was stirred at 50 °C for 1 h, 1-iodo-4-methylbenzene (2.0 mmol) and indole (3.0 mmol) were added, and then the mixture was stirred at 110 °C for 24 h. After the completion of the reaction, the mixture was cooled, then the precipitate was removed by filtration and the product was extracted with ethyl acetate (20 mL × 3). The collected organic layer was washed with brine, dried with MgSO4, filtered and concentrated in vacuo. The residue was purified directly by flash column chromatography.

1-Methyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (2)

White solid (85% yield), mp 154–155 °C. 1H NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 8.0, 1.3 Hz, 1H), 7.51–7.45 (m, 1H), 7.36–7.32 (m, 1H), 7.30 (d, J = 8.3 Hz, 1H), 4.90 (q, J = 8.3 Hz, 2H), 3.74 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 151.03, 149.21, 131.10, 128.96, 127.14, 126.86, 123.21, 122.10 (q, J = 278.5 Hz), 112.79, 61.78 (q, J = 37.8 Hz), 28.60. 19F NMR (471 MHz, CDCl3) δ −73.02. HRMS (ESI): calculated for C11H9F3N2O2+: 259.0689 [M + H]+, found: 259.0686.

1-Ethyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (3)

White solid (82% yield), mp 126–127 °C. 1H NMR (500 MHz, CDCl3) δ 7.66 (dd, J = 8.2, 1.5 Hz, 1H), 7.50–7.45 (m, 1H), 7.35–7.30 (m, 2H), 4.90 (q, J = 8.3 Hz, 2H), 4.36 (q, J = 7.2 Hz, 2H), 1.40 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 152.03, 149.71, 130.99, 130.32, 128.16, 128.14, 124.03, 123.15 (q, J = 278.5 Hz), 113.67, 62.81 (q, J = 37.8 Hz), 37.87, 12.36. 19F NMR (471 MHz, CDCl3) δ −73.00. HRMS (ESI): calculated for C12H11F3N2O2+: 273.0846 [M + H]+, found: 273.0849.

1-Butyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (4)

White solid (80% yield), mp 118–119 °C. 1H NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 7.9, 1.3 Hz, 1H), 7.50–7.44 (m, 1H), 7.31 (dd, J = 13.1, 8.1 Hz, 2H), 4.89 (q, J = 8.3 Hz, 2H), 4.33–4.26 (m, 2H), 1.79–1.72 (m, 2H), 1.49 (dd, J = 15.1, 7.5 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 152.04, 149.94, 131.28, 130.29, 128.12, 128.05, 123.99, 123.15 (q, J = 278.5 Hz), 113.84, 62.82 (q, J = 37.8 Hz), 42.62, 29.25, 20.22, 13.76. 19F NMR (471 MHz, CDCl3) δ −73.01. HRMS (ESI): calculated for C14H15F3N2O2+: 301.1159 [M + H]+, found: 301.1154.

1-Isopentyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (5)

White solid (87% yield), mp 123–124 °C. 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.8 Hz, 1H), 7.50–7.45 (m, 1H), 7.34–7.27 (m, 2H), 4.88 (q, J = 8.3 Hz, 2H), 4.32–4.26 (m, 2H), 1.78 (dd, J = 13.3, 6.6 Hz, 1H), 1.67–1.62 (m, 2H), 1.04 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 152.01, 149.86, 131.22, 130.32, 128.13, 128.09, 124.00, 123.15 (q, J = 278.5 Hz), 113.75, 62.83 (q, J = 37.8 Hz), 41.44, 35.82, 26.44, 22.47. 19F NMR (471 MHz, CDCl3) δ −72.56. HRMS (ESI): calculated for C15H17F3N2O2+: 315.1315 [M + H]+, found: 315.1318.

1-(Cyclopropylmethyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (6)

White solid (81% yield), mp 136–137 °C. 1H NMR (500 MHz, CDCl3) δ 7.66 (dd, J = 7.9, 1.0 Hz, 1H), 7.51–7.45 (m, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 7.5 Hz, 1H), 4.90 (q, J = 8.3 Hz, 2H), 4.23 (d, J = 7.0 Hz, 2H), 1.31–1.25 (m, 1H), 0.62–0.53 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 152.18, 150.28, 131.50, 130.22, 128.09, 128.05, 124.02, 123.17 (q, J = 278.5 Hz), 114.09, 62.86 (q, J = 37.8 Hz), 46.74, 9.57, 4.13. 19F NMR (471 MHz, CDCl3) δ −72.97. HRMS (ESI): calculated for C14H13F3N2O2+: 299.1002 [M + H]+, found: 299.1006.

1-(Cyclohexylmethyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (7)

White solid (84% yield), mp 145–146 °C. 1H NMR (500 MHz, CDCl3) δ 7.57 (dd, J = 7.9, 1.4 Hz, 1H), 7.40–7.36 (m, 1H), 7.26–7.20 (m, 2H), 4.81 (q, J = 8.3 Hz, 2H), 4.10 (d, J = 7.3 Hz, 2H), 1.88–1.80 (m, 1H), 1.68–1.56 (m, 5H), 1.12 (t, J = 9.9 Hz, 5H). 13C NMR (126 MHz, CDCl3) δ 151.05, 149.37, 130.67, 129.20, 127.07, 126.89, 122.92, 122.12 (q, J = 278.5 Hz), 113.28, 61.83 (q, J = 37.8 Hz), 47.53, 35.46, 29.83, 25.11, 24.73. 19F NMR (471 MHz, CDCl3) δ −72.98. HRMS (ESI): calculated for C17H19F3N2O2+: 341.1472 [M + H]+, found: 341.1476.

Methyl-2-(2-oxo-3-(2,2,2-trifluoroethoxy)quinoxalin-1(2H)-yl)acetate (8)

White solid (73% yield), mp 133–134 °C. 1H NMR (500 MHz, CDCl3) δ 7.67 (dd, J = 8.0, 1.4 Hz, 1H), 7.47–7.41 (m, 1H), 7.37–7.31 (m, 1H), 7.06 (dd, J = 8.3, 0.7 Hz, 1H), 5.07 (s, 2H), 4.90 (q, J = 8.3 Hz, 2H), 3.78 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 167.30, 151.79, 149.97, 131.26, 130.04, 128.39, 128.23, 124.57, 123.09 (q, J = 278.5 Hz), 113.24, 62.98 (q, J = 37.8 Hz), 52.95, 43.75. 19F NMR (471 MHz, CDCl3) δ −73.00. HRMS (ESI): calculated for C13H11F3N2O4+: 317.0744 [M + H]+, found: 317.0746.

tert-Butyl-2-(2-oxo-3-(2,2,2-trifluoroethoxy)quinoxalin-1(2H)-yl)acetate (9)

White solid (70% yield), mp 127–128 °C. 1H NMR (500 MHz, CDCl3) δ 7.66 (dd, J = 8.0, 1.4 Hz, 1H), 7.47–7.41 (m, 1H), 7.35–7.29 (m, 1H), 7.05 (dd, J = 8.3, 0.7 Hz, 1H), 4.97 (s, 2H), 4.90 (q, J = 8.3 Hz, 2H), 1.46 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 165.76, 151.84, 149.96, 131.39, 130.00, 128.21, 128.16, 124.40, 123.09 (q, J = 278.5 Hz), 113.32, 83.41, 62.93 (q, J = 37.8 Hz), 44.54, 27.96. 19F NMR (471 MHz, CDCl3) δ −73.01. HRMS (ESI): calculated for C16H17F3N2O4+: 359.1213 [M + H]+, found: 359.1216.

1-Benzyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (10)

White solid (80% yield), mp 126–127 °C. 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.8 Hz, 1H), 7.31 (ddd, J = 22.1, 13.2, 5.1 Hz, 8H), 5.52 (s, 2H), 4.92 (q, J = 8.2 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 152.11, 150.45, 134.91, 131.44, 130.22, 128.98, 128.15, 128.00, 127.87, 127.03, 124.27, 122.05 (q, J = 278.5 Hz), 114.67, 62.98 (q, J = 37.8 Hz), 46.42. 19F NMR (471 MHz, CDCl3) δ −72.94. HRMS (ESI): calculated for C17H13F3N2O2+: 335.1002 [M + H]+, found: 335.1008.

1-(2-Fluorobenzyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (11)

White solid (70% yield), mp 141–142 °C. 1H NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 7.9, 1.4 Hz, 1H), 7.40–7.35 (m, 1H), 7.31–7.28 (m, 1H), 7.26–7.23 (m, 2H), 7.15–7.07 (m, 2H), 7.05–7.00 (m, 1H), 5.58 (s, 2H), 4.93 (q, J = 8.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 160.30 (d, J = 245.7 Hz), 152.02, 150.62, 131.15, 130.17, 129.65 (d, J = 7.6 Hz), 128.72 (d, J = 3.8 Hz), 128.36, 128.03, 124.76 (d, J = 3.8 Hz), 124.43, 123.15 (q, J = 278.5 Hz), 122.00 (d, J = 13.8 Hz), 115.59 (d, J = 21.4 Hz), 114.26 (d, J = 2.5 Hz), 63.00 (q, J = 37.8 Hz), 39.83 (d, J = 5.0 Hz). 19F NMR (471 MHz, CDCl3) δ −72.95, −118.26. HRMS (ESI): calculated for C17H12F4N2O2+: 353.0908 [M + H]+, found: 353.0905.

1-(2-Chlorobenzyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (12)

White solid (69% yield), mp 150–151 °C. 1H NMR (500 MHz, CDCl3) δ 7.67 (dd, J = 7.8, 1.6 Hz, 1H), 7.45 (dd, J = 8.0, 0.9 Hz, 1H), 7.36–7.32 (m, 1H), 7.30 (td, J = 7.6, 1.3 Hz, 1H), 7.22 (td, J = 7.9, 1.2 Hz, 1H), 7.13–7.08 (m, 1H), 7.04 (dd, J = 8.2, 1.1 Hz, 1H), 6.81 (d, J = 7.7 Hz, 1H), 5.61 (s, 2H), 4.94 (q, J = 8.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 152.02, 150.47, 132.63, 131.92, 131.15, 130.18, 129.82, 128.99, 128.39, 128.00, 127.39, 127.00, 124.49, 123.12 (q, J = 278.5 Hz), 114.58, 63.02 (q, J = 37.8 Hz), 44.00. 19F NMR (471 MHz, CDCl3) δ −72.92. HRMS (ESI): calculated for C17H12ClF3N2O2+: 369.0612 [M + H]+, found: 369.0615.

1-(3-Methylbenzyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (13)

White solid (78% yield), mp 127–128 °C. 1H NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 7.9, 1.4 Hz, 1H), 7.37–7.33 (m, 1H), 7.30–7.26 (m, 2H), 7.23–7.18 (m, 1H), 7.07 (d, J = 5.6 Hz, 3H), 5.49 (s, 2H), 4.93 (q, J = 8.3 Hz, 2H), 2.30 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.13, 150.47, 138.82, 134.83, 131.51, 130.22, 128.81, 128.65, 128.14, 127.95, 127.60, 124.22, 124.06, 123.15 (q, J = 278.5 Hz), 114.73, 62.98 (q, J = 37.8 Hz), 46.47, 21.41. 19F NMR (471 MHz, CDCl3) δ −72.94. HRMS (ESI): calculated for C18H15F3N2O2+: 349.1159 [M + H]+, found: 349.1155.

1-(3-Chlorobenzyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (14)

White solid (72% yield), mp 149–150 °C. 1H NMR (500 MHz, CDCl3) δ 7.67 (dd, J = 7.9, 1.4 Hz, 1H), 7.40–7.35 (m, 1H), 7.31 (td, J = 7.8, 1.2 Hz, 1H), 7.26 (d, J = 4.7 Hz, 3H), 7.19 (dd, J = 8.3, 0.8 Hz, 1H), 7.17–7.10 (m, 1H), 5.49 (s, 2H), 4.93 (q, J = 8.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 152.03, 150.38, 136.92, 134.96, 131.23, 130.28, 130.23, 128.28, 128.20, 128.15, 127.11, 125.19, 124.47, 123.11 (q, J = 278.5 Hz), 114.38, 63.04 (q, J = 37.8 Hz), 45.91. 19F NMR (471 MHz, CDCl3) δ −72.94. HRMS (ESI): calculated for C17H12ClF3N2O2+: 369.0612 [M + H]+, found: 369.0615.

1-(3-Bromobenzyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (15)

White solid (75% yield), mp 154–155 °C. 1H NMR (500 MHz, CDCl3) δ 7.67 (dd, J = 7.9, 1.5 Hz, 1H), 7.44–7.35 (m, 3H), 7.33–7.28 (m, 1H), 7.22–7.17 (m, 3H), 5.48 (s, 2H), 4.93 (q, J = 8.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 152.02, 150.37, 137.19, 131.22, 131.15, 130.54, 130.22, 129.98, 128.30, 128.15, 125.66, 124.48, 123.11 (q, J = 278.5 Hz), 123.10, 114.37, 63.04 (q, J = 37.8 Hz), 45.84. 19F NMR (471 MHz, CDCl3) δ −72.94. HRMS (ESI): calculated for C17H12BrF3N2O2+: 413.0107 [M + H]+, found: 413.0109.

1-(4-Methylbenzyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (16)

White solid (83% yield), mp 171–172 °C. 1H NMR (500 MHz, CDCl3) δ 7.63 (dd, J = 8.2, 1.5 Hz, 1H), 7.36–7.32 (m, 1H), 7.29–7.25 (m, 2H), 7.17 (d, J = 8.1 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 5.47 (s, 2H), 4.91 (q, J = 8.3 Hz, 2H), 2.30 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.11, 150.44, 137.63, 131.91, 131.45, 130.21, 129.62, 128.11, 127.95, 127.07, 124.19, 123.16 (q, J = 278.5 Hz), 114.69, 62.95 (q, J = 37.8 Hz), 46.20, 21.08. 19F NMR (471 MHz, CDCl3) δ −72.94. HRMS (ESI): calculated for C18H15F3N2O2+: 349.1159 [M + H]+, found: 349.1157.

1-(4-Chlorobenzyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (17)

White solid (77% yield), mp 184–185 °C. 1H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 7.9 Hz, 1H), 7.39–7.34 (m, 1H), 7.32–7.27 (m, 3H), 7.21 (dd, J = 11.8, 8.3 Hz, 3H), 5.49 (s, 2H), 4.92 (q, J = 8.2 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 152.05, 150.39, 133.82, 133.41, 131.22, 130.24, 129.18, 128.51, 128.22, 128.15, 124.43, 123.10 (q, J = 278.5 Hz), 114.39, 63.01 (q, J = 37.8 Hz), 45.80. 19F NMR (471 MHz, CDCl3) δ −72.96. HRMS (ESI): calculated for C17H12ClF3N2O2+: 369.0612 [M + H]+, found: 369.0617.

1-(4-Bromobenzyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (18)

White solid (80% yield), mp 197–198 °C. 1H NMR (500 MHz, CDCl3) δ 7.66 (dd, J = 7.9, 1.5 Hz, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.39–7.34 (m, 1H), 7.30 (td, J = 7.7, 1.3 Hz, 1H), 7.19 (dd, J = 8.3, 1.1 Hz, 1H), 7.16 (d, J = 8.5 Hz, 2H), 5.47 (s, 2H), 4.92 (q, J = 8.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 152.04, 150.40, 133.94, 132.13, 131.20, 130.24, 128.82, 128.23, 128.15, 124.45, 121.99 (q, J = 278.5 Hz), 121.88, 114.39, 63.01 (q, J = 37.8 Hz), 45.86. 19F NMR (471 MHz, CDCl3) δ −72.97. HRMS (ESI): calculated for C17H12BrF3N2O2+: 413.0107 [M + H]+, found: 413.0106.

1-(4-Nitrobenzyl)-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (19)

White solid (64% yield), mp 193–194 °C. 1H NMR (500 MHz, CDCl3) δ 8.19 (d, J = 8.7 Hz, 2H), 7.69 (dd, J = 7.8, 1.6 Hz, 1H), 7.44 (d, J = 8.7 Hz, 2H), 7.38 (td, J = 7.9, 1.6 Hz, 1H), 7.33 (td, J = 7.6, 1.2 Hz, 1H), 7.12 (dd, J = 8.2, 1.0 Hz, 1H), 5.62 (s, 2H), 4.94 (q, J = 8.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 151.97, 150.35, 147.66, 142.18, 131.00, 130.27, 128.41, 128.39, 127.87, 124.76, 124.28, 123.06 (q, J = 278.5 Hz), 114.04, 63.09 (q, J = 37.8 Hz), 45.85. 19F NMR (471 MHz, CDCl3) δ −72.96. HRMS (ESI): calculated for C17H12F3N3O4+: 380.0853 [M + H]+, found: 380.0856.

1,6-Dimethyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (20)

White solid (80% yield), mp 164–165 °C. 1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 8.1 Hz, 1H), 7.15 (d, J = 8.2 Hz, 1H), 7.09 (s, 1H), 4.88 (q, J = 8.4 Hz, 2H), 3.73 (s, 3H), 2.50 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 151.43, 150.32, 138.62, 131.93, 127.86, 127.53, 125.37, 123.15 (q, J = 278.5 Hz), 114.03, 62.70 (q, J = 37.8 Hz), 29.53, 21.86. 19F NMR (471 MHz, CDCl3) δ −73.04. HRMS (ESI): calculated for C12H11F3N2O2+: 273.0846 [M + H]+, found: 273.0848.

6-Methoxy-1-methyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (21)

White solid (82% yield), mp 169–170 °C. 1H NMR (500 MHz, CDCl3) δ 7.20 (d, J = 9.1 Hz, 1H), 7.13 (d, J = 2.8 Hz, 1H), 7.08 (dd, J = 9.1, 2.9 Hz, 1H), 4.90 (q, J = 8.3 Hz, 2H), 3.88 (s, 3H), 3.72 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 156.47, 152.57, 149.75, 130.82, 126.20, 123.12 (q, J = 278.5 Hz), 116.53, 114.65, 110.27, 62.79 (q, J = 37.8 Hz), 55.75, 29.73. 19F NMR (471 MHz, CDCl3) δ −73.12. HRMS (ESI): calculated for C12H11F3N2O3+: 289.0795 [M + H]+, found: 289.0794.

6-Chloro-1-methyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (22)

White solid (72% yield), mp 145–146 °C. 1H NMR (500 MHz, CDCl3) δ 7.58–7.55 (m, 1H), 7.32–7.29 (m, 1H), 7.29 (s, 1H), 4.88 (q, J = 8.3 Hz, 2H), 3.71 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.05, 149.95, 133.96, 132.95, 128.86, 128.52, 124.54, 121.15 (q, J = 278.5 Hz), 113.95, 62.93 (q, J = 37.8 Hz), 29.76. 19F NMR (471 MHz, CDCl3) δ −73.02. HRMS (ESI): calculated for C11H8ClF3N2O2+: 293.0299 [M + H]+, found: 293.0296.

6-Bromo-1-methyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (23)

White solid (75% yield), mp 151–152 °C. 1H NMR (500 MHz, CDCl3) δ 7.50 (dd, J = 7.7, 1.2 Hz, 1H), 7.45–7.42 (m, 2H), 4.88 (q, J = 8.3 Hz, 2H), 3.71 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.20, 149.89, 133.15, 129.07, 128.91, 127.43, 121.15 (q, J = 278.5 Hz), 121.76, 116.90, 62.94 (q, J = 37.8 Hz), 29.76. 19F NMR (471 MHz, CDCl3) δ −73.02. HRMS (ESI): calculated for C11H8BrF3N2O2+: 336.9794 [M + H]+, found: 336.9798.

6-Benzoyl-1-methyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (24)

White solid (58% yield), mp 167–168 °C. 1H NMR (500 MHz, CDCl3) δ 8.08 (d, J = 1.9 Hz, 1H), 8.00 (dd, J = 8.7, 1.9 Hz, 1H), 7.81 (d, J = 7.7 Hz, 2H), 7.64 (t, J = 7.5 Hz, 1H), 7.53 (t, J = 7.7 Hz, 2H), 7.41 (d, J = 8.7 Hz, 1H), 4.90 (q, J = 8.3 Hz, 2H), 3.80 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 194.98, 152.62, 150.16, 137.36, 135.12, 133.39, 132.66, 130.25, 129.91, 129.61, 129.31, 128.50, 122.97 (q, J = 278.5 Hz), 114.01, 63.01 (q, J = 37.8 Hz), 29.96. 19F NMR (471 MHz, CDCl3) δ −72.93. HRMS (ESI): calculated for C18H13F3N2O3+: 363.0951 [M + H]+, found: 363.0953.

1-Methyl-6-nitro-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (25)

Yellow solid (45% yield), mp 172–173 °C. 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 2.4 Hz, 1H), 7.61 (dd, J = 9.0, 2.4 Hz, 1H), 7.27 (d, J = 9.0 Hz, 1H), 4.90 (q, J = 8.3 Hz, 2H), 3.67 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 151.23, 149.38, 133.57, 133.29, 131.31, 130.89, 130.02, 123.15 (q, J = 278.5 Hz), 115.23, 63.33 (q, J = 37.8 Hz), 29.40. 19F NMR (471 MHz, CDCl3) δ −73.12. HRMS (ESI): calculated for C11H8F3N3O4+: 304.0540 [M + H]+, found: 304.0543.

1,6,7-Trimethyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (26)

White solid (80% yield), mp 137–138 °C. 1H NMR (500 MHz, CDCl3) δ 7.40 (s, 1H), 7.04 (s, 1H), 4.87 (q, J = 8.4 Hz, 2H), 3.70 (s, 3H), 2.39 (s, 3H), 2.33 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 151.53, 150.24, 137.59, 133.13, 129.99, 128.09, 128.01, 123.21 (q, J = 278.5 Hz), 114.47, 62.66 (q, J = 37.8 Hz), 29.53, 20.32, 19.19. 19F NMR (471 MHz, CDCl3) δ −73.02. HRMS (ESI): calculated for C13H13F3N2O2+: 287.1002 [M + H]+, found: 287.1004.

6,7-Dichloro-1-methyl-3-(2,2,2-trifluoroethoxy)quinoxalin-2(1H)-one (27)

White solid (70% yield), mp 160–161 °C. 1H NMR (500 MHz, CDCl3) δ 7.74 (s, 1H), 7.38 (s, 1H), 4.87 (q, J = 8.2 Hz, 2H), 3.70 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.80, 149.63, 132.13, 131.52, 129.23, 128.71, 128.02, 122.89 (q, J = 278.5 Hz), 115.32, 63.09 (q, J = 37.8 Hz), 29.92. 19F NMR (471 MHz, CDCl3) δ −73.00. HRMS (ESI): calculated for C11H7Cl2F3N2O2+: 326.9910 [M + H]+, found: 326.9915.

3-(2,2,2-Trifluoroethoxy)quinoxalin-2(1H)-one (28)

Brown solid (75% yield), mp 195–196 °C. 1H NMR (500 MHz, DMSO) δ 12.63 (s, 1H), 7.64–7.60 (m, 1H), 7.49–7.44 (m, 1H), 7.36–7.30 (m, 2H), 5.11 (q, J = 8.9 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 153.28, 150.26, 131.31, 129.74, 128.20, 126.78, 124.23 (q, J = 278.5 Hz), 123.97, 115.66, 62.71 (q, J = 37.8 Hz). 19F NMR (471 MHz, CDCl3) δ −72.87. HRMS (ESI): calculated for C10H7F3N2O2+: 245.0533 [M + H]+, found: 245.0536.

3-(2,2,2-Trifluoroethoxy)-2H-benzo[b][1,4]oxazin-2-one (29)

White solid (78% yield), mp 157–158 °C. 1H NMR (500 MHz, CDCl3) δ 7.56 (dd, J = 7.9, 1.5 Hz, 1H), 7.45–7.40 (m, 1H), 7.37–7.30 (m, 2H), 4.87 (q, J = 8.2 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 149.02, 148.54, 145.60, 129.02, 128.84, 127.12, 125.95, 122.73 (q, J = 278.5 Hz), 116.35, 63.40 (q, J = 37.8 Hz). 19F NMR (471 MHz, CDCl3) δ −73.17. HRMS (ESI): calculated for C10H6F3NO3+: 246.0373 [M + H]+, found: 246.0373.

1-Methyl-3-(2,2,3,3,3-pentafluoropropoxy)quinoxalin-2(1H)-one (30)

White solid (83% yield), mp 110–111 °C. 1H NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 8.0, 1.4 Hz, 1H), 7.49 (ddd, J = 8.7, 7.4, 1.5 Hz, 1H), 7.36–7.32 (m, 1H), 7.30 (dd, J = 8.4, 1.0 Hz, 1H), 4.97 (td, J = 12.9, 0.9 Hz, 2H), 3.74 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.07, 150.13, 132.15, 129.92, 128.21, 127.88, 124.24, 119.72–117.15 (m), 113.82, 61.73 (t, J = 27.7 Hz), 29.59. 19F NMR (471 MHz, CDCl3) δ −83.67, −122.90. HRMS (ESI): calculated for C12H9F5N2O2+: 309.2153 [M + H]+, found: 309.2155.

3-(2,2,3,3,4,4,4-Heptafluorobutoxy)-1-methylquinoxalin-2(1H)-one (31)

White solid (79% yield), mp 135–136 °C. 1H NMR (500 MHz, CDCl3) δ 7.66 (dd, J = 8.0, 1.4 Hz, 1H), 7.50–7.46 (m, 1H), 7.36–7.32 (m, 1H), 7.30 (d, J = 8.3 Hz, 1H), 5.01 (t, J = 13.5 Hz, 2H), 3.74 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.08, 150.11, 132.13, 129.90, 128.18, 127.86, 124.21, 119.72–117.15 (m), 113.80, 61.81 (t, J = 27.7 Hz), 29.57. 19F NMR (471 MHz, CDCl3) δ −80.74, −119.93, −127.51. HRMS (ESI): calculated for C13H9F7N2O2+: 359.0625 [M + H]+, found: 359.0627.

1-Methyl-3-(2,2,3,3-tetrafluoropropoxy)quinoxalin-2(1H)-one (32)

White solid (72% yield), mp 131–132 °C. 1H NMR (500 MHz, CDCl3) δ 7.59 (dd, J = 8.0, 1.3 Hz, 1H), 7.43–7.38 (m, 1H), 7.29–7.25 (m, 1H), 7.23 (d, J = 8.3 Hz, 1H), 6.08 (tt, J = 53.0, 5.0 Hz, 1H), 4.78 (t, J = 12.2 Hz, 2H), 3.67 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.11, 150.18, 132.04, 130.06, 128.13, 127.89, 124.25, 113.79, 114.59–106.74 (m), 62.85 (t, J = 27.7 Hz), 29.55. 19F NMR (471 MHz, CDCl3) δ −124.57, −139.29. HRMS (ESI): calculated for C12H10F4N2O2+: 291.0751 [M + H]+, found: 291.0752.

1-Methyl-3-(4,4,4-trifluorobutoxy)quinoxalin-2(1H)-one (33)

White solid (78% yield), mp 108–109 °C. 1H NMR (500 MHz, CDCl3) δ 7.55 (dd, J = 7.9, 1.4 Hz, 1H), 7.38–7.32 (m, 1H), 7.23 (td, J = 7.8, 1.2 Hz, 1H), 7.21–7.18 (m, 1H), 4.47 (t, J = 6.3 Hz, 2H), 3.65 (s, 3H), 2.32–2.23 (m, 2H), 2.09 (dt, J = 13.5, 6.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 153.56, 150.92, 131.64, 130.91, 127.60, 127.26, 127.02 (q, J = 275.9 Hz), 124.02, 113.65, 65.60, 30.74 (q, J = 29.0 Hz), 29.46, 21.46 (q, J = 2.5 Hz). 19F NMR (471 MHz, CDCl3) δ −66.31. HRMS (ESI): calculated for C13H13F3N2O2+: 287.1002 [M + H]+, found: 287.1006.

3-(2,2-Difluoroethoxy)-1-methylquinoxalin-2(1H)-one (34)

White solid (73% yield), mp 128–129 °C. 1H NMR (500 MHz, CDCl3) δ 7.58 (dd, J = 7.9, 1.4 Hz, 1H), 7.42–7.37 (m, 1H), 7.26 (td, J = 8.0, 1.2 Hz, 1H), 7.22 (dd, J = 8.4, 0.8 Hz, 1H), 6.19 (tt, J = 55.4, 4.4 Hz, 1H), 4.61 (td, J = 13.0, 4.4 Hz, 2H), 3.67 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 152.66, 150.49, 131.97, 130.29, 127.89, 127.82, 124.19, 113.76, 112.91 (t, J = 241.9 Hz), 65.34 (t, J = 31.5 Hz), 29.58. 19F NMR (471 MHz, CDCl3) δ −125.03. HRMS (ESI): calculated for C11H10F2N2O2+: 241.0783 [M + H]+, found: 241.0787.

3-(2-Fluoroethoxy)-1-methylquinoxalin-2(1H)-one (35)

White solid (80% yield), mp 136–137 °C. 1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 7.9 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.20–7.17 (m, 1H), 4.83–4.80 (m, 1H), 4.74–4.71 (m, 1H), 4.70–4.67 (m, 1H), 4.66–4.61 (m, 1H), 3.65 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 153.42, 150.78, 131.72, 130.68, 127.59, 127.36, 123.97, 113.65, 80.96 (d, J = 171.4 Hz), 66.03 (d, J = 21.4 Hz), 29.48. 19F NMR (471 MHz, CDCl3) δ −224.30. HRMS (ESI): calculated for C11H11FN2O2+: 223.0878 [M + H]+, found: 223.0879.

3-(2,2-Difluoroethoxy)-1-ethylquinoxalin-2(1H)-one (36)

White solid (70% yield), mp 102–103 °C. 1H NMR (500 MHz, CDCl3) δ 7.59 (dd, J = 8.4, 1.5 Hz, 1H), 7.45–7.34 (m, 1H), 7.25 (t, J = 7.4 Hz, 2H), 6.19 (tt, J = 55.4, 4.4 Hz, 1H), 4.61 (td, J = 13.0, 4.4 Hz, 2H), 4.29 (q, J = 7.2 Hz, 2H), 1.32 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 152.65, 149.96, 130.82, 130.63, 128.11, 127.87, 123.98, 113.62, 112.94 (t, J = 241.9 Hz), 65.32 (t, J = 31.5 Hz), 37.79, 12.36. 19F NMR (471 MHz, CDCl3) δ −124.95. HRMS (ESI): calculated for C12H12F2N2O2+: 255.0940 [M + H]+, found: 255.0946.

1-Isopentyl-3-(2,2,3,3-tetrafluoropropoxy)quinoxalin-2(1H)-one (37)

White solid (75% yield), mp 119–120 °C. 1H NMR (500 MHz, CDCl3) δ 7.58 (dd, J = 8.0, 1.3 Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.25 (t, J = 7.6 Hz, 1H), 7.21 (d, J = 8.4 Hz, 1H), 6.10 (tt, J = 53.0, 5.0 Hz, 1H), 4.75 (t, J = 12.1 Hz, 2H), 4.22–4.17 (m, 2H), 1.71–1.69 (m, 1H), 1.59–1.54 (m, 2H), 0.97 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 152.06, 149.86, 131.14, 130.43, 128.17, 128.10, 124.07, 113.75, 114.43–107.04 (m), 62.94 (t, J = 27.7 Hz), 41.45, 35.81, 26.45, 22.45. 19F NMR (471 MHz, CDCl3) δ −124.65, −139.38. HRMS (ESI): calculated for C16H18F4N2O2+: 347.1377 [M + H]+, found: 347.1379.

1-Butyl-3-(2,2,3,3,4,4,4-heptafluorobutoxy)quinoxalin-2(1H)-one (38)

White solid (74% yield), mp 129–130 °C. 1H NMR (500 MHz, CDCl3) δ 7.66 (dd, J = 7.9, 1.3 Hz, 1H), 7.49–7.45 (m, 1H), 7.31 (dd, J = 13.9, 7.6 Hz, 2H), 5.00 (t, J = 13.5 Hz, 2H), 4.31–4.25 (m, 2H), 1.80–1.72 (m, 2H), 1.49 (dd, J = 15.1, 7.5 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 152.10, 149.84, 131.31, 130.23, 128.13, 128.10, 123.99, 119.72–117.15 (m), 113.85, 61.88 (t, J = 27.7 Hz), 42.65, 29.24, 20.23, 13.76. 19F NMR (471 MHz, CDCl3) δ −80.74, −119.93, −127.51. HRMS (ESI): calculated for C16H15F7N2O2+: 401.1095 [M + H]+, found: 401.1098.

6-Bromo-3-(2-fluoroethoxy)-1-methylquinoxalin-2(1H)-one (39)

White solid (78% yield), mp 172–173 °C. 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 2.2 Hz, 1H), 7.52 (dd, J = 8.8, 2.3 Hz, 1H), 7.14 (d, J = 8.9 Hz, 1H), 4.90–4.87 (m, 1H), 4.79 (dd, J = 5.0, 3.6 Hz, 1H), 4.77–4.74 (m, 1H), 4.70 (dd, J = 5.0, 3.6 Hz, 1H), 3.71 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 154.16, 150.49, 131.80, 130.93, 130.14, 130.00, 116.64, 115.05, 80.87 (d, J = 171.4 Hz), 66.38 (d, J = 21.4 Hz), 29.71. 19F NMR (471 MHz, CDCl3) δ −224.13. HRMS (ESI): calculated for C11H10BrFN2O2+: 300.9983 [M + H]+, found: 300.9989.

6-Bromo-1-methyl-3-(4,4,4-trifluorobutoxy)quinoxalin-2(1H)-one (40)

White solid (70% yield), mp 119–120 °C. 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 2.2 Hz, 1H), 7.52 (dd, J = 8.8, 2.2 Hz, 1H), 7.13 (d, J = 8.8 Hz, 1H), 4.53 (t, J = 6.3 Hz, 2H), 3.70 (s, 3H), 2.38–2.30 (m, 2H), 2.17 (dd, J = 15.3, 6.6 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 154.24, 150.59, 132.00, 130.82, 130.11, 130.02, 126.98 (q, J = 277.2 Hz), 116.66, 115.03, 65.96, 30.72 (q, J = 29.0 Hz), 29.67, 21.44 (q, J = 3.8 Hz). 19F NMR (471 MHz, CDCl3) δ −66.21. HRMS (ESI): calculated for C13H12BrF3N2O2+: 365.0107 [M + H]+, found: 365.0108.

1,6,7-Trimethyl-3-(2,2,3,3,3-pentafluoropropoxy)quinoxalin-2(1H)-one (41)

White solid (74% yield), mp 132–133 °C. 1H NMR (500 MHz, CDCl3) δ 7.41 (s, 1H), 7.05 (s, 1H), 4.94 (td, J = 13.0, 0.7 Hz, 2H), 3.71 (s, 3H), 2.40 (s, 3H), 2.34 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 151.58, 150.15, 137.61, 133.10, 130.04, 128.10, 127.96, 119.72–117.15 (m), 114.47, 61.57 (t, J = 27.7 Hz), 29.50, 20.33, 19.19. 19F NMR (471 MHz, CDCl3) δ −83.70, −122.92. HRMS (ESI): calculated for C14H13F5N2O2+: 337.0970 [M + H]+, found: 337.0972.

6,7-Dichloro-3-(4-methylpiperazin-1-yl)quinoxalin-2(1H)-one (45)

Yellow solid (63% yield), mp 234–235 °C. 1H NMR (500 MHz, DMSO) δ 7.46 (s, 1H), 7.39 (s, 1H), 3.92 (s, 4H), 2.45–2.37 (m, 4H), 2.19 (s, 3H). 13C NMR (126 MHz, DMSO) δ 151.78, 151.27, 132.56, 129.34, 125.49, 125.40, 124.63, 115.39, 54.62, 45.98, 45.68. HRMS (ESI): calculated for C13H14Cl2N4O+: 313.0618 [M + H]+, found: 313.0615.

3,3′-Bis(2,2,2-trifluoroethoxy)-2,2′-biquinoxaline (46)

White solid (50% yield), mp 213–214 °C. 1H NMR (500 MHz, CDCl3) δ 8.24–8.19 (m, 1H), 7.99–7.95 (m, 1H), 7.84–7.78 (m, 1H), 7.74–7.69 (m, 1H), 4.93 (q, J = 8.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 153.67, 142.47, 140.16, 139.50, 131.49, 129.71, 128.09, 127.19, 123.16 (q, J = 278.5 Hz), 62.62 (q, J = 37.8 Hz). 19F NMR (471 MHz, CDCl3) δ −72.93. HRMS (ESI): calculated for C20H12F6N4O2+: 455.0937 [M + H]+, found: 455.0939.

1-(p-Tolyl)-1H-indole (49)

Yellow liquid (71% yield), 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 7.7 Hz, 1H), 7.52 (dd, J = 8.2, 0.6 Hz, 1H), 7.37 (d, J = 8.3 Hz, 2H), 7.31–7.27 (m, 3H), 7.22–7.18 (m, 1H), 7.17–7.13 (m, 1H), 6.65 (dd, J = 3.2, 0.6 Hz, 1H), 2.42 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 137.34, 136.36, 136.02, 130.19, 129.22, 128.11, 124.37, 122.24, 121.10, 120.22, 110.55, 103.23, 21.09.

Conflicts of interest

There are no conflicts to declare.

Supplementary Material

RA-010-C9RA10194B-s001
RA-010-C9RA10194B-s002

Acknowledgments

This work was supported by Natural Science Foundation of Shandong Province (ZR2017LB006).

†

Electronic supplementary information (ESI) available: Detailed experimental procedures and analytical data. CCDC 1958968. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9ra10194b

Notes and references

  1. (a) Irurre J. Casas J. Messeguer A. Bioorg. Med. Chem. Lett. 1993;3:179. doi: 10.1016/S0960-894X(01)80872-6. [DOI] [PubMed] [Google Scholar]; (b) Legros J. Dehli J. R. Bolm C. Adv. Synth. Catal. 2005;347:19. doi: 10.1002/adsc.200404206. [DOI] [Google Scholar]; (c) Reddy M. R. Shibata N. Kondo Y. Nakamura S. Toru T. Angew. Chem., Int. Ed. 2006;45:8163. doi: 10.1002/anie.200603590. [DOI] [PubMed] [Google Scholar]; (d) Bégué J.-P. and Bonnet-Delpon D., Bioorganic and Medicinal Chemistry of Fluorine, Wiley, Hoboken, 2008 [Google Scholar]
  2. (a) Nakai T. Tanaka K. Ishikawa N. J. Fluorine Chem. 1977;9:89. doi: 10.1016/S0022-1139(00)82560-9. [DOI] [Google Scholar]; (b) Idoux J. P. Gupton J. T. McCurry C. K. Crews A. D. Jurss C. D. Colon C. Rampi R. C. J. Org. Chem. 1983;48:3771. doi: 10.1021/jo00169a033. [DOI] [Google Scholar]; (c) Kamal A. Pratap T. B. Ramana K. V. Ramana A. V. Babu A. H. Tetrahedron Lett. 2002;43:7353. doi: 10.1016/S0040-4039(02)01719-7. [DOI] [Google Scholar]; (d) Shen X. Neumann C. N. Kleinlein C. Goldberg N. W. Ritter T. Angew. Chem., Int. Ed. 2015;54:5662. doi: 10.1002/anie.201500902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. (a) Huang R. Huang Y. Lin X. Rong M. Weng Z. Angew. Chem., Int. Ed. 2015;54:5736. doi: 10.1002/anie.201501257. [DOI] [PubMed] [Google Scholar]; (b) Huang Y. Huang R. Weng Z. Synlett. 2015;26:2327. doi: 10.1055/s-0035-1560054. [DOI] [Google Scholar]; (c) Guo Y. Li Y.-D. Chen C. Zhao J.-H. Liu H.-W. Liao D.-H. Ji Y.-F. Res. Chem. Intermed. 2016;42:2525. doi: 10.1007/s11164-015-2165-4. [DOI] [Google Scholar]; (d) Vuluga D. Legros J. Crousse B. Bonnet-Delpon D. Eur. J. Org. Chem. 2009:3513. doi: 10.1002/ejoc.200900303. [DOI] [PubMed] [Google Scholar]; (e) Zhang K. Xu X.-H. Qing F.-L. J. Fluorine Chem. 2017;196:24. doi: 10.1016/j.jfluchem.2016.07.008. [DOI] [Google Scholar]; (f) Rangarajan T. M. Singh R. Brahma R. Devi K. Singh R. P. Singh R. P. Prasad A. K. Chem.–Eur. J. 2014;20:14218. doi: 10.1002/chem.201404121. [DOI] [PubMed] [Google Scholar]; (g) Yang L. Li S. Cai L. Ding Y. Fu L. Cai Z. Ji H. Li G. Org. Lett. 2017;19:2746. doi: 10.1021/acs.orglett.7b01103. [DOI] [PubMed] [Google Scholar]
  4. (a) The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, London, 2002 [Google Scholar]; (b) Nair D. Scarpello J. White L. Freista dos Santos L. Vankelecom I. Livingston A. Tetrahedron Lett. 2001;42:8219. doi: 10.1016/S0040-4039(01)01734-8. [DOI] [Google Scholar]; (c) Garett C. Prasad K. Adv. Synth. Catal. 2004;346:889. doi: 10.1002/adsc.200404071. [DOI] [Google Scholar]
  5. (a) Shi L.-L. Zhou H. Wu J.-F. Li X. Mini-Rev. Org. Chem. 2015;12:96. doi: 10.2174/1570193X11666141029004418. [DOI] [Google Scholar]; (b) Shi L. Hu W. Wu J. Zhou H. Zhou H. Li X. Mini-Rev. Med. Chem. 2018;18:392. doi: 10.2174/1389557517666171101111134. [DOI] [PubMed] [Google Scholar]; (c) Carta A. Piras S. Loriga G. Paglietti G. Mini-Rev. Med. Chem. 2006;6:1179. doi: 10.2174/138955706778742713. [DOI] [PubMed] [Google Scholar]; (d) Li X. Yang K. Li W. Xu W. Drugs Future. 2006;31:979. doi: 10.1358/dof.2006.031.11.1037128. [DOI] [Google Scholar]; (e) Ishi-i T. Yaguma K. Kuwahara R. Taguri Y. Mataka S. Org. Lett. 2006;8:585. doi: 10.1021/ol052779t. [DOI] [PubMed] [Google Scholar]
  6. (a) Wang F. Hu B.-L. Liu L. Tu H.-Y. Zhang X.-G. J. Org. Chem. 2017;82:11247. doi: 10.1021/acs.joc.7b01930. [DOI] [PubMed] [Google Scholar]; (b) Mtiraoui H. Renault K. Sanselme M. Msaddek M. Renard P.-Y. Sabot C. Org. Biomol. Chem. 2017;15:3060. doi: 10.1039/C7OB00205J. [DOI] [PubMed] [Google Scholar]; (c) Klemme R. Bentz C. Zukowski T. Schefzig L. Lentz D. Reissig H.-U. Zimmer R. Synthesis. 2016;48:1491. doi: 10.1055/s-0035-1561751. [DOI] [Google Scholar]; (d) Yang T. Zhu H. Yu W. Org. Biomol. Chem. 2016;14:3376. doi: 10.1039/C6OB00226A. [DOI] [PubMed] [Google Scholar]; (e) Li D. Ma H. Yu W. Adv. Synth. Catal. 2015;357:3696. doi: 10.1002/adsc.201500774. [DOI] [Google Scholar]; (f) Jiang H. An X. Tong K. Zheng T. Zhan Y. Yu S. Angew. Chem., Int. Ed. 2015;54:4055. doi: 10.1002/anie.201411342. [DOI] [PubMed] [Google Scholar]; (g) An X.-D. Yu S. Org. Lett. 2015;17:2692. doi: 10.1021/acs.orglett.5b01096. [DOI] [PubMed] [Google Scholar]
  7. (a) Ke Q. Yan G. Yu J. Wu X. Org. Biomol. Chem. 2019;17:5863. doi: 10.1039/C9OB00782B. [DOI] [PubMed] [Google Scholar]; (b) Mao P. Zhu J. Yuan J. Yang L. Xiao Y. Zhang C. Chin. J. Org. Chem. 2019;39:1529. doi: 10.6023/cjoc201904025. [DOI] [Google Scholar]
  8. (a) Gao M. Li Y. Xie L. Chauvin R. Cui X. Chem. Commun. 2016;52:2846. doi: 10.1039/C5CC08049E. [DOI] [PubMed] [Google Scholar]; (b) Wang J. Li J. Wei Y. Yang J. Huo C. Org. Chem. Front. 2018;5:3534. doi: 10.1039/C8QO01049H. [DOI] [Google Scholar]; (c) Kim Y. Kim D. Y. Tetrahedron Lett. 2018;59:2443. doi: 10.1016/j.tetlet.2018.05.034. [DOI] [Google Scholar]; (d) Mai W.-P. Yuan J.-W. Zhu J.-L. Li Q.-Q. Yang L. R. Xiao Y.-M. Mao P. Qu L.-B. ChemistrySelect. 2019;4:11066. doi: 10.1002/slct.201903478. [DOI] [Google Scholar]
  9. (a) Gupta A. Deshmukh M. S. Jain N. J. Org. Chem. 2017;82:4784. doi: 10.1021/acs.joc.7b00464. [DOI] [PubMed] [Google Scholar]; (b) Hoang T. T. To T. A. Cao V. T. T. Nguyen A. T. Nguyen T. T. Phan N. T. S. Catal. Commun. 2017;101:20. doi: 10.1016/j.catcom.2017.07.012. [DOI] [Google Scholar]; (c) Wei W. Wang L. Bao P. Shao Y. Yue H. Yang D. Yang X. Zhao X. Wang H. Org. Lett. 2018;20:7125. doi: 10.1021/acs.orglett.8b03079. [DOI] [PubMed] [Google Scholar]; (d) Yang Q. Zhang Y. Sun Q. Shang K. Zhang H.-Y. Zhao J. Adv. Synth. Catal. 2018;360:4509. doi: 10.1002/adsc.201801076. [DOI] [Google Scholar]; (e) Yang Q. Yang Z. Tan Y. Zhao J. Sun Q. Zhang H.-Y. Zhang Y. Adv. Synth. Catal. 2019;361:1662. doi: 10.1002/adsc.201801661. [DOI] [Google Scholar]; (f) Yuan J.-W. Zhu J.-L. Li B. Yang L.-Y. Mao P. Zhang S.-R. Li Y.-C. Qu L.-B. Org. Biomol. Chem. 2019;17:10178–10187. doi: 10.1039/C9OB02157D. [DOI] [PubMed] [Google Scholar]
  10. (a) Wei W. Wang L. Yue H. Bao P. Liu W. Hu C. Yang D. Wang H. ACS Sustainable Chem. Eng. 2018;6:17252. doi: 10.1021/acssuschemeng.8b04652. [DOI] [Google Scholar]; (b) Fu J. Yuan J. Zhang Y. Xiao Y. Mao P. Diao X. Qu L. Org. Chem. Front. 2018;5:3382. doi: 10.1039/C8QO00979A. [DOI] [Google Scholar]; (c) Hu L. Yuan J. Fu J. Zhang T. Gao L. Xiao Y. Mao P. Qu L. Eur. J. Org. Chem. 2018:4113. doi: 10.1002/ejoc.201800697. [DOI] [Google Scholar]; (d) Liu S. Huang Y. Qing F.-L. Xu X.-H. Org. Lett. 2018;20:5497. doi: 10.1021/acs.orglett.8b02451. [DOI] [PubMed] [Google Scholar]; (e) Yuan J. Fu J. Yin J. Dong Z. Xiao Y. Mao P. Qu L. Org. Chem. Front. 2018;5:2820. doi: 10.1039/C8QO00731D. [DOI] [Google Scholar]; (f) Zhang W. Pan Y.-L. Yang C. Chen L. Li X. Cheng J.-P. J. Org. Chem. 2019;84:7786. doi: 10.1021/acs.joc.9b00657. [DOI] [PubMed] [Google Scholar]; (g) Xue W. Su Y. Wang K.-H. Zhang R. Feng Y. Cao L. Huang D. Hu Y. Org. Biomol. Chem. 2019;17:6654. doi: 10.1039/C9OB01169B. [DOI] [PubMed] [Google Scholar]; (h) Liu L. X. Pan N. Sheng W. Su L. Liu L. Dong J. Y. Zhou Y. B. Yin S. F. Adv. Synth. Catal. 2019;361:4126. doi: 10.1002/adsc.201900572. [DOI] [Google Scholar]; (i) Yan Z. Sun B. Zhang X. Zhuang X. Yang J. Su W. Jin C. Chem.–Asian J. 2019;14:3344. doi: 10.1002/asia.201900904. [DOI] [PubMed] [Google Scholar]; (j) Xie L.-Y. Jiang L.-L. Tan J.-X. Wang Y. Xu X.-Q. Zhang B. Cao Z. He W.-M. ACS Sustainable Chem. Eng. 2019;7:14153. doi: 10.1021/acssuschemeng.9b02822. [DOI] [Google Scholar]
  11. (a) Yin K. Zhang R. Org. Lett. 2017;19:1530. doi: 10.1021/acs.orglett.7b00310. [DOI] [PubMed] [Google Scholar]; (b) Yuan J. Liu S. Qu L. Adv. Synth. Catal. 2017;359:4197. doi: 10.1002/adsc.201701058. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Yin K. Zhang R. Synlett. 2018;29:597. doi: 10.1055/s-0036-1589139. [DOI] [Google Scholar]; (d) Noikham M. Kittikool T. Yotphan S. Synthesis. 2018;50:2337. doi: 10.1055/s-0037-1609445. [DOI] [Google Scholar]; (e) Ramesh B. Reddy C. R. Kumar G. R. Reddy B. V. S. Tetrahedron Lett. 2018;59:628. doi: 10.1016/j.tetlet.2017.12.085. [DOI] [Google Scholar]
  12. (a) Zeng X. Liu C. Wang X. Zhang J. Wang X. Hu Y. Org. Biomol. Chem. 2017;15:8929. doi: 10.1039/C7OB02187A. [DOI] [PubMed] [Google Scholar]; (b) Yuan J.-W. Fu J.-H. Liu S.-N. Xiao Y.-M. Mao P. Qu L.-B. Org. Biomol. Chem. 2018;16:3203. doi: 10.1039/C8OB00206A. [DOI] [PubMed] [Google Scholar]; (c) Xie L.-Y. Peng S. Fan T.-G. Liu Y.-F. Sun M. Jiang L.-L. Wang X.-X. Cao Z. He W.-M. Sci. China: Chem. 2019;62:460. doi: 10.1007/s11426-018-9446-1. [DOI] [Google Scholar]
  13. (a) Wei Z. Qi S. Xu Y. Liu H. Wu J. Li H.-S. Xia C. Duan G. Adv. Synth. Catal. 2019;361:5490. doi: 10.1002/adsc.201900885. [DOI] [Google Scholar]; (b) Wang J. Sun B. Zhang L. Xu T. Xie Y. Jin C. Asian J. Org. Chem. 2019;8:1942. doi: 10.1002/ajoc.201900414. [DOI] [Google Scholar]; (c) Wang L. Zhang Y. Li F. Hao X. Zhang H.-Y. Zhao J. Adv. Synth. Catal. 2018;360:3969. doi: 10.1002/adsc.201800863. [DOI] [Google Scholar]; (d) Xue W. Su Y. Wang K.-H. Cao L. Feng Y. Zhang W. Huang D. Hu Y. Asian J. Org. Chem. 2019;8:887. doi: 10.1002/ajoc.201900118. [DOI] [Google Scholar]
  14. (a) Hong G. Yuan J. Fu J. Pan G. Wang Z. Yang L. Xiao Y. Mao P. Zhang X. Org. Chem. Front. 2019;6:1173. doi: 10.1039/C9QO00105K. [DOI] [Google Scholar]; (b) Wang L. Liu H. Li F. Zhao J. Zhang H.-Y. Zhang Y. Adv. Synth. Catal. 2019;361:2354. doi: 10.1002/adsc.201900066. [DOI] [Google Scholar]; (c) Jin C. Zhuang X. Sun B. Li D. Zhu R. Asian J. Org. Chem. 2019;8:1490. doi: 10.1002/ajoc.201900369. [DOI] [Google Scholar]
  15. (a) Zhao L. Wang L. Gao Y. Wang Z. Li P. Adv. Synth. Catal. 2019;361:5363. doi: 10.1002/adsc.201900732. [DOI] [Google Scholar]; (b) Zhou J. Zhou P. Zhao T. Ren Q. Li J. Adv. Synth. Catal. 2019;361:5371. doi: 10.1002/adsc.201901008. [DOI] [Google Scholar]; (c) Yang Q. Han X. Zhao J. Zhang H.-Y. Zhang Y. J. Org. Chem. 2019;84:11417. doi: 10.1021/acs.joc.9b01181. [DOI] [PubMed] [Google Scholar]
  16. (a) Teng Q.-H. Yao Y. Wei W.-X. Tang H.-T. Li J.-R. Pan Y.-M. Green Chem. 2019;21:6241. doi: 10.1039/C9GC03045J. [DOI] [Google Scholar]; (b) Xie L.-Y. Chen Y.-L. Qin L. Wen Y. Xie J.-W. Tan J.-X. Huang Y. Cao Z. He W.-M. Org. Chem. Front. 2019;6:3950. doi: 10.1039/C9QO01240K. [DOI] [Google Scholar]
  17. Xu J. Yang H. Cai H. Bao H. Li W. Zhang P. Org. Lett. 2019;21:4698. doi: 10.1021/acs.orglett.9b01578. [DOI] [PubMed] [Google Scholar]
  18. (a) Liu K.-J. Duan Z.-H. Zeng X.-L. Sun M. Tang Z. Jiang S. Cao Z. He W.-M. ACS Sustainable Chem. Eng. 2019;7:10293. doi: 10.1021/acssuschemeng.9b00002. [DOI] [Google Scholar]; (b) Xie L.-Y. Fang T.-G. Tan J.-X. Zhang B. Cao Z. Yang L.-H. He W.-M. Green Chem. 2019;21:3858. doi: 10.1039/C9GC01175G. [DOI] [Google Scholar]; (c) Xie L.-Y. Qu J. Peng S. Liu K.-J. Wang Z. Ding M.-H. Wang Y. Cao Z. He W.-M. Green Chem. 2018;20:760. doi: 10.1039/C7GC03106H. [DOI] [Google Scholar]; (d) Liu B. Jin F. Wang T. Yuan X. Han W. Angew. Chem., Int. Ed. 2017;56:12712. doi: 10.1002/anie.201707006. [DOI] [PubMed] [Google Scholar]; (e) Yang B. Lu Z. ACS Catal. 2017;7:8362. doi: 10.1021/acscatal.7b02892. [DOI] [Google Scholar]; (f) Yang S. Li P. Wang Z. Wang L. Org. Lett. 2017;19:3386. doi: 10.1021/acs.orglett.7b01230. [DOI] [PubMed] [Google Scholar]; (g) Xie L.-Y. Li Y.-J. Qu J. Duan Y. Hu J. Liu K.-J. Cao Z. He W.-M. Green Chem. 2017;19:5642. doi: 10.1039/C7GC02304A. [DOI] [Google Scholar]; (h) Zhu X. Li P. Shi Q. Wang L. Green Chem. 2016;18:6373. doi: 10.1039/C6GC01487A. [DOI] [Google Scholar]; (i) Wang X. Wang C. Liu Y. Xiao J. Green Chem. 2016;18:4605. doi: 10.1039/C6GC01272H. [DOI] [Google Scholar]; (j) Cheng X. Yang B. Hu X. Xu Q. Lu Z. Chem.–Eur. J. 2016;22:17566. doi: 10.1002/chem.201604440. [DOI] [PubMed] [Google Scholar]
  19. (a) Narayanam J. M. R. Stephenson C. R. J. Chem. Soc. Rev. 2011;40:102. doi: 10.1039/B913880N. [DOI] [PubMed] [Google Scholar]; (b) Pan X. Xia H. Wu J. Org. Chem. Front. 2016;3:1163. doi: 10.1039/C6QO00153J. [DOI] [Google Scholar]; (c) Nagib D. A. MacMillan D. W. C. Nature. 2011;480:224. doi: 10.1038/nature10647. [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Pham P. V. Nagib D. A. MacMillan D. W. C. Angew. Chem., Int. Ed. 2011;50:6119. doi: 10.1002/anie.201101861. [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Yoon T. P. Ischay M. A. Du J. Nat. Chem. 2010;2:527. doi: 10.1038/nchem.687. [DOI] [PubMed] [Google Scholar]; (f) Ye Y. Sanford M. S. J. Am. Chem. Soc. 2012;134:9034. doi: 10.1021/ja301553c. [DOI] [PMC free article] [PubMed] [Google Scholar]; (g) Li L. Mu X. Liu W. Wang Y. Mi Z. Li C.-J. J. Am. Chem. Soc. 2016;138:5809. doi: 10.1021/jacs.6b02782. [DOI] [PubMed] [Google Scholar]; (h) Yu X.-L. Chen J.-R. Chen D.-Z. Xiao W.-J. Chem. Commun. 2016;52:8275. doi: 10.1039/C6CC03335K. [DOI] [PubMed] [Google Scholar]; (i) Xiang Y. Kuang Y. Wu J. Org. Chem. Front. 2016;3:901. doi: 10.1039/C6QO00120C. [DOI] [Google Scholar]; (j) Xiang H. Zhao Q. Tang Z. Xiao J. Xia P. Wang C. Yang C. Chen X. Yang H. Org. Lett. 2017;19:146. doi: 10.1021/acs.orglett.6b03441. [DOI] [PubMed] [Google Scholar]; (k) Qin H.-T. Wu S.-W. Liu J.-L. Liu F. Chem. Commun. 2017;53:1696. doi: 10.1039/C6CC10035J. [DOI] [PubMed] [Google Scholar]; (l) Dai P. Yu X. Teng P. Zhang W.-H. Deng C. Org. Lett. 2018;20:6901. doi: 10.1021/acs.orglett.8b02965. [DOI] [PubMed] [Google Scholar]; (m) Rawner T. Lutsker E. Kaiser C. Reiser O. ACS Catal. 2018;8:3950. doi: 10.1021/acscatal.8b00847. [DOI] [Google Scholar]; (n) Zou L. Li P. Wang B. Wang L. Chem. Commun. 2019;55:3737. doi: 10.1039/C9CC01014A. [DOI] [PubMed] [Google Scholar]; (o) Zhao L. Li P. Zhang H. Wang L. Org. Chem. Front. 2019;6:87. doi: 10.1039/C8QO01079J. [DOI] [Google Scholar]; (p) Liu Y. Chen X.-L. Sun K. Li X.-Y. Zeng F.-L. Liu X.-C. Qu L.-B. Zhao Y.-F. Yu B. Org. Lett. 2019;21:4019. doi: 10.1021/acs.orglett.9b01175. [DOI] [PubMed] [Google Scholar]; (q) Zeng F.-L. Sun K. Chen X.-L. Yuan X.-Y. He S.-Q. Liu Y. Peng Y.-Y. Qu L.-B. Lv Q.-Y. Yu B. Adv. Synth. Catal. 2019;361:5176. doi: 10.1002/adsc.201901016. [DOI] [Google Scholar]
  20. (a) Xia C. Wang K. Wang G. Duan G. Org. Biomol. Chem. 2018;16:2214. doi: 10.1039/C8OB00511G. [DOI] [PubMed] [Google Scholar]; (b) Han J. Wang G. Sun J. Li H. Duan G. Li F. Xia C. Catal. Commun. 2019;118:81. doi: 10.1016/j.catcom.2018.10.001. [DOI] [Google Scholar]; (c) You G. Wang K. Wang X. Wang G. Sun J. Duan G. Xia C. Org. Lett. 2018;20:4005. doi: 10.1021/acs.orglett.8b01395. [DOI] [PubMed] [Google Scholar]
  21. Edwards J. P. Venable J. D. Quinoxaline compounds. US 20050070527A1, March 2005. Chem. Abstr. 2005;142:355284. [Google Scholar]
  22. Haneda S. Adachi Y. Hayashi M. Tetrahedron. 2009;65:10459. doi: 10.1016/j.tet.2009.10.014. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

RA-010-C9RA10194B-s001
RA-010-C9RA10194B-s001.pdf (6.1MB, pdf)
RA-010-C9RA10194B-s002
RA-010-C9RA10194B-s002.cif (22.8KB, cif)

Articles from RSC Advances are provided here courtesy of Royal Society of Chemistry

RESOURCES